Photo: d3sign/Getty Images
The White House unveiled agreements with pharma giants Eli Lilly and Company and Novo Nordisk to offer GLP-1's Zepbound, orforglipron, Ozempic and Wegovy through the prescription digital marketplace TrumpRx.
TrumpRx, which was announced in September, is a marketplace that allows consumers to purchase drugs directly through the government instead of through insurance at a discounted price.
Through the agreement, the White House says Novo Nordisk's Ozempic and Wegovy will decrease in price from around $1,000 and $1,350 per month to $350 when purchased through TrumpRx.
Eli Lilly and Company's Zepbound and orforglipron, if approved by the FDA, will fall from around $1,086 per month to an average of $346 when purchased through the prescription marketplace.
Zepbound (tirzepatide) is an FDA-approved multi-dose pen used for obesity and sleep apnea.
Orforglipron is Lilly's once-daily obesity pill that has not yet been approved by the FDA. Lilly says it "applied for the Commissioner's National Priority Voucher for orforglipron, potentially accelerating U.S. FDA approval."
"Starting as early as April 1, 2026, Medicare beneficiaries will pay no more than $50 per month for Zepbound (tirzepatide), available in a multi-dose pen, and for orforglipron, Lilly's convenient once-daily obesity pill, provided both receive approval from the U.S. Food and Drug Administration (FDA). States will also have the ability to expand access to Zepbound and orforglipron through Medicaid," Lilly said in a statement.
Additionally, the White House says other Eli Lilly and Novo Nordisk medications will be available via TrumpRx, including migraine medication Emgality, which will sell at $299 per pen, down from its list price of $443, and diabetes medication Trulicity, which will retail for $389 per month, down from $598.
Novo Nordisk will also provide commonly used insulin products at $35 per month of supply, including NovoLog, a rapid-acting insulin for type 1 and type 2 diabetes, and Tresiba, an ultra-long-acting basal insulin to help control blood sugar in patients with diabetes.
Additionally, should Novo Nordisk's Wegovy pill receive FDA approval, or any other oral similar GLP-1 drugs made by either Novo Nordisk or Eli Lilly, the initial dose of those medicines will be made available via TrumpRx for $150 per month.
"The agreement also provides that Eli Lilly and Novo Nordisk will guarantee MFN [most-favored nation] prices on all new medicines that they bring to market, repatriate increased foreign revenue on existing products, and provide every State Medicaid program in the country access to MFN drug prices on their products," the White House said in a statement.
The pharma giants also announced commitments to increase U.S. manufacturing, with Novo Nordisk committing an additional $10 billion investment "to strengthen its domestic footprint, including producing the Wegovy tablet, if approved, end-to-end in the U.S.," and Eli Lilly announcing an at least $27 billion investment in new U.S. manufacturing.
THE LARGER TREND
The Trump administration announced the launch of TrumpRx in September alongside a deal with Pfizer to lower the price of many prescription medications in the U.S.
Through the deal, patients can purchase Pfizer's Eucrisa, a topical ointment for atopic dermatitis, at an 80% discount; Xeljanz, an oral medication for rheumatoid arthritis, psoriatic arthritis and ulcerative colitis, available at a 40% discount; and Zavzpret, a drug for treating migraines, at a 50% discount.
At the time, the deal also gave Pfizer a three-year grace period on President Donald Trump’s tariffs on pharmaceutical drugs made overseas, which were expected to take effect Oct. 1, but Trump subsequently delayed enforcement in order to continue negotiations with pharma companies regarding lowering drug prices and onshore manufacturing.
A month later, Cigna and CVS Health signed on to take part in TrumpRx beginning in January 2026. The pair will dispense all EMD Serono treatments for infertility on the TrumpRx platform.
Cigna, through its Evernorth pharmacies, Freedom Fertility and VFP Pharmacy Group, will dispense Gonal-f, Cetrotide and Ovidrel.
CVS Health said it will also offer fertility drug access through its CVS specialty pharmacy and 9,000 retail stores. The price of Gonal-f will be lowered by 84%.
